27236033|t|LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease
27236033|a|Lipoproteins play a central role in the development of atherosclerotic disease. So, with their ability to affect lipid levels, the LDLR, ApoB and ApoE polymorphisms could be one of the factors influencing development of atherosclerosis. This hypothesis has been tested in different populations with conflicting results. The purpose of the present study was to investigate the association between the LDLR, ApoB and ApoE genes polymorphisms with premature CAD (PCAD) in Egyptians. One hundred thirty-five patients of PCAD and one hundred thirty-two ages and sex matched control subjects were included in the study. LDLR and ApoB genes polymorphisms were analyzed by polymerase chain reaction (PCR). The ApoE genotypes were identified by multiplex amplification refractory mutation system (multi-AMRS). We found that LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele increased the risk of PCAD by 1.8, 2.1 and 12.1 respectively. The present study proved that smoking, metabolic syndrome, ApoB X(+)X(+) genotype and ApoE E4 allele were independent risk factors for the development of PCAD. This is the first study investigate the association between low density lipoprotein receptor, apolipoprotein B and apolipoprotein E genes polymorphisms with PCAD and lipid levels in Egyptians and we concluded that the LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may be associated with an increased risk for development of PCAD by elevated levels of total cholesterol (TC) and low density lipoprotein (LDLc). The coexistence of CAD risk factors with LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may increase the risk of the development of PCAD in Egyptian patients.
27236033	0	4	LDLR	T028	C1366529
27236033	6	10	ApoB	T028	C1412471
27236033	15	25	ApoE genes	T028	C1412481
27236033	26	39	polymorphisms	T045	C0678951
27236033	54	66	risk factors	T033	C0035648
27236033	70	103	premature coronary artery disease	T047	C1867743
27236033	104	116	Lipoproteins	T116,T123	C0023820
27236033	144	155	development	T169	C1527148
27236033	159	182	atherosclerotic disease	T047	C0004153
27236033	217	229	lipid levels	T034	C0428460
27236033	235	239	LDLR	T028	C1366529
27236033	241	245	ApoB	T028	C1412471
27236033	250	254	ApoE	T028	C1412481
27236033	255	268	polymorphisms	T045	C0678951
27236033	309	320	development	T169	C1527148
27236033	324	339	atherosclerosis	T047	C0004153
27236033	346	356	hypothesis	T078	C1512571
27236033	366	372	tested	T170	C0392366
27236033	386	397	populations	T081	C0032659
27236033	464	475	investigate	T169	C1292732
27236033	504	508	LDLR	T028	C1366529
27236033	510	514	ApoB	T028	C1412471
27236033	519	529	ApoE genes	T028	C1412481
27236033	530	543	polymorphisms	T045	C0678951
27236033	549	562	premature CAD	T047	C1867743
27236033	564	568	PCAD	T047	C1867743
27236033	573	582	Egyptians	T098	C0337801
27236033	608	616	patients	T101	C0030705
27236033	620	624	PCAD	T047	C1867743
27236033	652	656	ages	T032	C0001779
27236033	661	664	sex	T032	C1522384
27236033	718	722	LDLR	T028	C1366529
27236033	727	737	ApoB genes	T028	C1412471
27236033	738	751	polymorphisms	T045	C0678951
27236033	757	765	analyzed	T062	C0936012
27236033	769	794	polymerase chain reaction	T063	C0032520
27236033	796	799	PCR	T063	C0032520
27236033	806	810	ApoE	T028	C1412481
27236033	811	820	genotypes	T032	C0017431
27236033	840	890	multiplex amplification refractory mutation system	T059	C2732542
27236033	892	902	multi-AMRS	T059	C2732542
27236033	919	932	LDLR A(+)A(+)	T028	C1366529
27236033	933	941	genotype	T032	C0017431
27236033	943	952	ApoB X(+)	T028	C1412471
27236033	953	959	allele	T028	C0002085
27236033	964	971	ApoE E4	T028	C1412481
27236033	972	978	allele	T028	C0002085
27236033	1001	1005	PCAD	T047	C1867743
27236033	1071	1078	smoking	T055	C0037369
27236033	1080	1098	metabolic syndrome	T047	C0524620
27236033	1100	1113	ApoB X(+)X(+)	T028	C1412471
27236033	1114	1122	genotype	T032	C0017431
27236033	1127	1134	ApoE E4	T028	C1412481
27236033	1135	1141	allele	T028	C0002085
27236033	1159	1171	risk factors	T033	C0035648
27236033	1180	1191	development	T169	C1527148
27236033	1195	1199	PCAD	T047	C1867743
27236033	1225	1236	investigate	T169	C1292732
27236033	1261	1293	low density lipoprotein receptor	T028	C1366529
27236033	1295	1311	apolipoprotein B	T028	C1412471
27236033	1316	1338	apolipoprotein E genes	T028	C1412481
27236033	1339	1352	polymorphisms	T045	C0678951
27236033	1358	1362	PCAD	T047	C1867743
27236033	1367	1379	lipid levels	T034	C0428460
27236033	1383	1392	Egyptians	T098	C0337801
27236033	1419	1432	LDLR A(+)A(+)	T028	C1366529
27236033	1433	1441	genotype	T032	C0017431
27236033	1443	1452	ApoB X(+)	T028	C1412471
27236033	1453	1459	allele	T028	C0002085
27236033	1464	1471	ApoE E4	T028	C1412481
27236033	1472	1478	allele	T028	C0002085
27236033	1486	1501	associated with	T080	C0332281
27236033	1524	1535	development	T169	C1527148
27236033	1539	1543	PCAD	T047	C1867743
27236033	1556	1588	levels of total cholesterol (TC)	T059	C0201950
27236033	1593	1616	low density lipoprotein	T059	C0202116
27236033	1618	1622	LDLc	T059	C0202116
27236033	1644	1647	CAD	T047	C1867743
27236033	1648	1660	risk factors	T033	C0035648
27236033	1666	1679	LDLR A(+)A(+)	T028	C1366529
27236033	1680	1688	genotype	T032	C0017431
27236033	1690	1699	ApoB X(+)	T028	C1412471
27236033	1700	1706	allele	T028	C0002085
27236033	1711	1718	ApoE E4	T028	C1412481
27236033	1719	1725	allele	T028	C0002085
27236033	1755	1766	development	T169	C1527148
27236033	1770	1774	PCAD	T047	C1867743
27236033	1778	1786	Egyptian	T098	C0337801
27236033	1787	1795	patients	T101	C0030705